BRAF and non-small cell lung carcinoma: The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) study revealed that treatment with ICIs resulted in a similar OS in 27 BRAF mutated and 323 WT NSCLC patients with a median OS 10 m vs. 11 m, P = 0.334 [28].